Impact of White Matter Hyperintensities on progression in Alzheimer's disease Comparison of Amyloid Biomarkers in Alzheimer's Disease-a Monocentric Study

摘要: Background and aims: Cerebral white matter hyperintensities (WMH) have been suggested to contribute progression in Alzheimer's disease (AD). Quantification of WMH patients can be performed both manually, where is categorized according the Fazekas scale, automatically using software which calculates based on a FLAIR MRI sequence. The aim this study was investigate extent WMH-burden affects mixed population clinical AD prodromal AD. Furthermore, we assessed whether manual rating automatic segmentation provide equal information progression. Methods: Patients with diagnosis MCI suspected having early were included. Evaluation by an experienced clinician at 12-month follow-up visit. Manual evaluation (Fazekas scale) neuroradiologist as previously described (Koikkalainen et al, 2016, Neuroimage). examined for association between baseline after 12 months stratified without CVD CVD. Results: There no significant difference status either (p=0.122) or (p=0.159). However, there trend higher progressed vs. stable diagnosed Conclusion: seems impact only when present large amounts. We are currently investigating prognostic value measurements. According international criteria, amyloid-biomarkers diagnostic elements Controversies about their accuracy differential may explained distinct pathological processes between-center variability amyloid-markers. pretended compare agreement amyloid CSF-biomarkers, [11C]-Pittsburgh Compound Positron Emission Tomography (PIB-PET) Florbetapir (18F) these biomarkers diagnosis. 96 least two markers course considered gold standard. used locally established cutoffs CSF-AD biomarkers-Aβ42